Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Common Equity (2016 - 2025)

Rocket Pharmaceuticals (RCKT) has disclosed Common Equity for 10 consecutive years, with $277.2 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 40.16% to $277.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $277.2 million through Dec 2025, down 40.16% year-over-year, with the annual reading at $277.2 million for FY2025, 40.16% down from the prior year.
  • Common Equity hit $277.2 million in Q4 2025 for Rocket Pharmaceuticals, down from $313.7 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $541.1 million in Q3 2023 to a low of $277.2 million in Q4 2025.
  • Historically, Common Equity has averaged $422.2 million across 5 years, with a median of $429.6 million in 2022.
  • Biggest five-year swings in Common Equity: soared 100.82% in 2021 and later tumbled 40.16% in 2025.
  • Year by year, Common Equity stood at $454.7 million in 2021, then increased by 7.69% to $489.7 million in 2022, then grew by 0.59% to $492.6 million in 2023, then dropped by 5.96% to $463.2 million in 2024, then crashed by 40.16% to $277.2 million in 2025.
  • Business Quant data shows Common Equity for RCKT at $277.2 million in Q4 2025, $313.7 million in Q3 2025, and $354.2 million in Q2 2025.